Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.

Christine S WalshMitchell KamravaAndré RogatkoSungjin KimAndrew LiIlana CassBeth KarlanBobbie J Rimel

Published in: PloS one (2021)

The addition of pembrolizumab to cisplatin and gemcitabine did not appear to provide benefit beyond chemotherapy alone in patients with recurrent platinum-resistant ovarian cancer.

Keyphrases

locally advanced
advanced non small cell lung cancer
rectal cancer
squamous cell carcinoma
radiation therapy
open label
randomized controlled trial